Added to YB: 2026-01-12
Pitch date: 2026-01-02
NVO [bullish]
Novo Nordisk A/S
+14.34%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.6T
Pitch Price
DKK 333.60
Price Target
N/A
Dividend
3.18%
EV/EBITDA
10.16
P/E
15.70
EV/Sales
5.38
Sector
Pharmaceuticals
Category
growth
50 Stocks for the New Year Pt 3 - Novo Nordisk A/S
NVO: Weight-loss drug distributor (Ozempic, Wegovy) with 5% YOY revenue growth, 13x P/E, 72% ROE. Tailwinds from aging Americans & processed food consumption driving obesity demand. Headwinds include Eli Lilly competition & patent expiries in some countries.
Read full article (1 min)